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Abstract
Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15% of the general population and in
severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote
angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver
costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue
compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ
delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the
phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We
found that LPA upregulates angiogenic growth factor production by ASC under two- and three-dimensional in vitro
models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell
migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine
critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this
method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude
less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a
novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for
treating ischemic diseases.
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Introduction
Peripheral vascular disease (PVD) affects more than 27
million people in Europe and North America and is
characterized by obstruction of blood flow to the extremities [1].
Closely linked risk factors include smoking, hypertension,
obesity, diabetes, and age, and severe cases lead to limb
necrosis and loss [2]. Unfortunately, surgical interventions for
acute PVD are invasive and expensive, necessitating the
development of other effective treatment options. One such
strategy involves the use of angiogenic cytokines such as the
potent endothelial cell mitogen vascular endothelial growth
factor (VEGF) to promote revascularization in situ [3,4].
However, such growth factors can be cost-prohibitive and
difficult to release in a controlled spatiotemporal manner,
raising concerns about awaking dormant tumor cells and
aberrant vessel formation.
The localized delivery of hydrogel-entrapped proangiogenic
cells provides an attractive alternative to current methods [5,6]
and obviates the need for additional recombinant proteins. For
example, bone marrow-derived mesenchymal stromal cells
(MSC) encapsulated in alginate beads improve angiogenesis in
ischemic mouse limbs [7]. However, further improvements in
function were obtained by transducing the cells to express
recombinant telomerase and exogenous peptides to elicit
paracrine effects [7], presenting major hurdles for clinical
implementation. Compared to MSC, adipose-derived stromal
cells (ASC) represent a more clinically appealing population
because they can be obtained using minimally invasive
procedures and with dramatically higher yields [8,9], allowing
for their direct use without further in vitro expansion.
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Furthermore, ASC secrete many angiogenic growth factors
including VEGF and have been targeted for use in vascular
and musculoskeletal regenerative medicine [6,10-12].
Lysophosphatidic acid (LPA) is an inexpensive, commercially
available glycerophospholipid that signals through multiple G-
protein coupled receptors and is naturally found in serum at low
micromolar levels [13,14]. LPA has diverse effects on many cell
types and regulates processes such as cell survival [15],
migration [16], and differentiation [17]. In particular, LPA
promotes VEGF secretion by human MSC [18,19]. This effect
is enhanced under hypoxia [20-22], making LPA a natural
target for stimulating trophic factor secretion and endothelial
cell recruitment in ischemic defects.
We hypothesized that LPA enhances the proangiogenic
effects of ASC under ischemia both in vitro and in vivo. We
tested our hypothesis by exposing human ASC to 25 μM LPA
under serum deprivation and hypoxia (SD/H) and examining
LPA receptor expression and transcriptional activity of
angiogenic growth factors. We assessed the functional effects
of LPA by measuring endothelial cell migration towards ASC-
conditioned media and quantifying VEGF secretion by ASC
suspended in fibrin gels with LPA. Finally, we determined the
therapeutic relevance of fibrin-entrapped ASC and LPA by
quantifying revascularization in a rigorous in vivo model of
critical hindlimb ischemia.
Materials and Methods
1.1. Cell culture
Human adipose-derived stromal cells from three male donors
(28, 39, and 60 years old) were separately isolated from
adipose tissue (National Disease Research Interchange,
Philadelphia, PA) as previously described [8]. Cells were
expanded in growth medium (GM) consisting of minimum
essential alpha medium (α-MEM, Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS, JR Scientific,
Woodland, CA) and 1% penicillin-streptomycin (P/S,
Mediatech, Manassas, VA). All angiogenic gene expression
assays were performed on each donor. Subsequently, ASC
from the 39 year old male were chosen as a representative
population for continued characterization and in vivo
implantation. Cells were cultured under standard conditions in
a humidified incubator and utilized at passages 4-5. All medium
was replaced every 3 days.
For all experiments examining the effects of SD/H, ASC were
seeded on 6-well tissue culture plates at 25,000 cells/cm2. After
attaching overnight, cells were washed 3x with PBS to
eliminate all traces of serum. To simulate ischemia, media was
replaced with serum-free GM supplemented with 0.1% (w/v)
fatty-acid free BSA, and cells were incubated in hypoxia for 24
h in Heracell 150i tri-gas incubators (Thermo Scientific,
Waltham, MA) at 1% oxygen (n = 6). ASC were supplemented
with LPA (Enzo Life Sciences, Plymouth Meeting, PA) to a final
concentration of 25 μM. A subset of cells received the LPA1/3
inhibitor Ki16425 (10 μM; Cayman Chemical, Ann Arbor, MI) to
abrogate LPA binding. Negative controls for ischemia were
cultured for the same duration in 21% O2 in GM with full serum.
1.2. qPCR analysis of angiogenic cytokine production
and LPA receptor expression
Total RNA was collected from ASC exposed to SD/H, with or
without LPA and Ki16425 (n = 4) using an RNeasy Mini kit
(Qiagen, Valencia, CA). 600 ng of total RNA was reverse
transcribed with the QuantiTect Reverse Transcription kit
(Qiagen). qPCR was performed using a QuantiFast Probe PCR
kit (Qiagen) on a Mastercycler realplex2 (Eppendorf, Westbury,
NY. Primers and probes for RPL13 (HS00204173_m1),
VEGFA (Hs00900055_m1), FGF2 (Hs00266645_m1), LPAR1
(Hs00173500_m1), LPAR2 (Hs01113287_m1), LPAR3
(Hs00173857_m1), LPAR4 (Hs00271072_s1), and LPAR5
(Hs00252675_s1) were purchased from Applied Biosystems
(Foster City, CA). Amplification conditions were 95°C for 3 min,
followed by 40 cycles at 95°C for 3 s and 60°C for 30 s.
Quantitative PCR results were normalized to RPL13 transcript
levels to yield ΔCt, and fold change in expression relative to the
housekeeping gene was calculating using 2-ΔCt.
1.3. Transwell migration assay
ASC were exposed to SD/H in the presence or absence of
LPA and Ki16425. Conditioned media was collected after 24 h
and mixed 1:4 with endothelial cell growth media (EGM2,
Lonza, Walkersville, MD) supplemented with 10% FBS and 1%
P/S, but no VEGF, FGF, or IGF (GF-def EGM2) [23]. 1×105
human endothelial colony forming cells (ECFC, generous gift of
Dr. Mervin Yoder, Indiana University) in 300 μL GF-def EGM2
were seeded on 24-well FluoroBlok™ cell culture inserts (3 μM
pore size, BD Biosciences, San Jose, CA) coated in 0.1%
bovine gelatin, and inserts were placed in 1 mL of conditioned
media mixture. Cells were incubated for 24 h, and cell
migration across the membrane was quantified by staining with
calcein AM and measuring fluorescence on a microplate reader
(Synergy HTTR, Wisnooski, VT) according to the
manufacturer’s instructions.
1.4. Fibrin gel fabrication
ASC were entrapped in fibrin gels containing 20 mg/mL
fibrinogen and 2.3% (w/v) NaCl as previously described [24].
Briefly, a solution of 40 mg/mL fibrinogen and 4.4% (w/v) NaCl
containing 25×106 ASC/mL was mixed in equal volume with a
solution containing 5 U/mL human thrombin and 40 mM CaCl2
in PBS. 80 μL of mixture was cast into each well of a
polydimethylsiloxane (PDMS) mold and allowed to gel for 1 h at
37°C [25]. When appropriate, LPA and Ki16425 were included
in the fibrinogen solution to yield a final concentration of 25 μM
and 10 μM, respectively.
1.5. Quantification of ASC angiogenic growth factor
production
VEGF secretion over 24 h into media by ASC entrapped in
fibrin gels in response to SD/H, 25 μM LPA, and 10 μM
Ki16425 was measured using a human VEGF ELISA kit
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN). Data were normalized to the quantity of total
DNA collected from the cells in each gel using a Quant-iT
PicoGreen dsDNA Assay Kit (Invitrogen) (n = 4). To further
Lysophosphatidic Acid Enhances ASC Angiogenesis
PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e82134
assess angiogenic trophic factor secretion, media was
analyzed using a RayBio® Human Angiogenesis Antibody
Array 1 (G-series, RayBiotech, Norcross, GA) according to the
manufacturer’s instructions.
1.6. Critical limb ischemia model
Treatment of experimental animals was in accordance with
UC Davis animal care guidelines and all National Institutes of
Health animal-handling procedures. The UC Davis IACUC
specifically approved the protocol. The hindlimb ischemia
protocol was performed largely as previously described [26].
Briefly, 16 week old nonobese diabetic/severe combined
immune deficient gamma (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ) mice (Jackson Laboratories – West, Sacramento, CA)
were anesthetized and maintained under a 2% isoflurane/O2
mixture delivered through a mask. Unilateral hindlimb ischemia
was surgically induced by exposing the right femoral artery and
vein and ligating the proximal portion of the femoral artery, the
distal portion of the saphenous artery and the remaining
collateral arteries after dissecting away the femoral nerve. The
ligated artery was excised, completely removed from the hind
limb, and fibrin gels containing 25 μM LPA, 1x106 ASC, or both
25 μM LPA and 1x106 ASC were positioned towards the
proximal ligation site (n = 10). Buprenorphine (0.05 mg/kg) was
administered for pain relief at the time of surgery and twice
daily for the next 3 days, and animals were allowed access to
food and water ad libitum.
Animals were euthanized 2 weeks post-surgery, and both the
non-operated and treated limbs were removed, fixed in 10%
formalin for 72 h, and transferred to 70% ethanol. The
quadriceps muscle from each limb was excised distal to the
defect site and processed for histology using standard
techniques. Paraffin-embedded specimens were sectioned at 5
μM for staining.
1.7. Blood vessel quantification
Large vessel density was quantified in both the uninjured
contralateral limb and treated limb for each animal using H&E
stained cross-sections at 100x magnification by a blinded
observer. Vessels were enumerated from 10 random fields of
view per sample by counting circular structures with well-
defined lumens containing more than one erythrocyte. The
presence of endothelial cells was determined by
immunohistochemistry using antibodies for mouse CD31
(ab124432, 1:1000, Abcam, Cambridge, MA) and a rabbit
specific HRP/DAB detection kit (ab64261, Abcam).
1.8. Statistical analysis
Data are presented as mean ± standard error unless
otherwise stated. Statistical analysis was performed using one-
way ANOVA with Tukey’s Multiple Comparison post-test where
applicable. P values less than 0.05 were considered
statistically significant.
Results
1.1. LPA induces VEGF and FGF2 expression through
LPA1
Since there are multiple receptors for LPA, we assessed
gene expression for LPAR1, LPAR2, LPAR3, LPAR4, and
LPAR5 in ASC to determine possible signaling pathways. We
also compared receptor transcription under standard culture
conditions with expression under SD/H to determine whether
ischemia might affect LPA sensitivity (Figure 1a-d). Although
LPAR2, LPAR4, and LPAR5 showed increased expression
under SD/H, the most prevalent receptor, LPAR1, remained
unchanged. LPAR3 was undetected in this cell population. We
then compared expression of genes encoding for two potent
angiogenic factors, VEGFA and basic fibroblast growth factor
(FGF2) under SD/H in the presence or absence of LPA (Figure
2a-b). Hypoxia alone induced greater VEGFA and FGF2
transcription compared to normoxia [27], but the addition of 25
μM LPA synergistically increased this effect. When we added
the competitive LPA1/3 inhibitor Ki16425 to LPA-treated cells,
changes in expression were completely abrogated. Thus,
based on high expression of LPAR1 and nearly undetectable
levels of LPAR3, together with the capacity of the LPA1/3
inhibitor to block the effects of LPA on ASC, we conclude that
these effects are mediated through LPA1.
1.2. ASC treated with LPA promote endothelial cell
migration
Because transcriptional activity does not necessarily
correspond to functional outcomes, we assessed the ability of
LPA-treated, ischemic ASC to attract endothelial cells. To avoid
potentially confounding effects of direct cell-cell interactions,
Figure 1.  LPA receptor expression in human ASC is
dependent on oxygen microenvironment.  (a) LPAR1
expression is unchanged by SD/H, but (b) LPAR2 expression
is significantly higher in SD/H. LPAR3 expression is
undetectable in either condition, but SD/H also increases
expression of (c) LPAR4 and (d) LPAR5 (n = 4). **p < 0.01 vs.
control, ***p < 0.001 vs. control.
doi: 10.1371/journal.pone.0082134.g001
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we incubated ASC under SD/H for 24 hours in the presence or
absence of LPA and collected the conditioned medium for use
in a transwell migration assay [23]. Human endothelial colony
forming cells (ECFC) were seeded in the top of a modified
Boyden chamber, and medium from ASC was placed in the
lower compartment to determine chemotactic effect (Figure
3a). In agreement with our qPCR data, significantly more
ECFC migrated toward medium from ASC exposed to LPA
under SD/H. Similarly, Ki16425 reversed the effects of LPA
conditioning. We also found that ECFC were not attracted to
unconditioned medium containing LPA alone, demonstrating
that endothelial cells are stimulated directly by ASC-secreted
factors.
Figure 2.  LPA enhances the proangiogenic effects of ASC
under ischemia in vitro.  Expression of (a) VEGF and (b)
FGF2 are upregulated by SD/H and further enhanced with the
addition of 25 μM LPA. In both cases, the addition of Ki16425
abrogates this effect (n = 4). Data represents combined gene
expression from three unique donors. *p < 0.05 vs. control, **p
< 0.01 vs. control, ***p < 0.001 vs. control.
doi: 10.1371/journal.pone.0082134.g002
1.3. LPA stimulates ASC VEGF secretion in 3D fibrin
gels
Practical applications for ASC-mediated therapeutic
angiogenesis require a biomaterial delivery system to maintain
cell localization and survival [5,24]. Therefore, we examined
the ability of LPA to maintain its proangiogenic effect in a 3D in
vitro model. We selected a fibrin hydrogel for our application
due to its native role in clots as a provisional matrix for
recruited endothelial and immune cells [28]. To replicate an in
vivo environment as accurately as possible, gels were
synthesized with an internal concentration of 25 μM LPA, but
no lipid was added to the surrounding culture medium (Figure
3b). Our 3D results reflect 2D gene expression – specifically,
ASC entrapped in fibrin gels containing LPA secrete
significantly higher amounts of VEGF into the surrounding
medium, while Ki16425 completely abolishes this effect.
We further examined the secretion of additional factors using
an angiogenesis antibody array (Figure 3c). These data
revealed that, in addition to producing higher levels of VEGF,
ASC entrapped in LPA-containing gels secrete more
angiogenin, another powerful angiogenic factor. Additionally,
these cells produced more MCP-1 (not shown), TIMP-2, and
RANTES, but less TGF-β1, suggesting that the addition of LPA
affects the immunomodulatory potency of ASC under SD/H.
Again, the addition of Ki16425 reversed the effects of LPA for
all cytokines.
1.4. Co-delivery of ASC and LPA significantly improves
critical limb ischemia recovery
We applied our findings in a rigorous model of critical limb
ischemia using NSG mice by creating a severe, unilateral
ischemic defect that leads to limb necrosis if left untreated. We
implanted fibrin gels containing LPA, ASC, or both LPA and
ASC over the ligated artery site and assessed intramuscular
vascularization 2 weeks post-surgery. H&E stained sections of
quadriceps distal to the femoral artery ligation site revealed
significantly more large blood vessels in limbs treated with gels
containing cells and LPA together (Figure 4a-d). Quantification
of these vessels, defined as clear circular structures with a
lumen and containing more than one erythrocyte, confirmed
this outcome (Figure 4i). To completely visualize all blood
vessels, including microcapillaries, we stained the histological
sections for CD31 (Figure 4e-h). In agreement with H&E
results, limbs treated with the combination of ASC and LPA
had more numerous vessels (Figure 4i). Of particular note,
mice receiving ASC and LPA lost fewer toes and experienced
less severe necrosis than mice receiving ASC alone, although
animals treated with LPA only had the least overall limb
damage (Figure 4j). Taken together with our in vitro data, these
findings demonstrate that the proangiogenic potential of ASC is
significantly increased when treated with LPA, and this strategy
has great translational potential for use in clinical conditions of
vascular disease.
Discussion
Therapeutic angiogenesis for treating PVD is frequently
pursued through the delivery of recombinant proteins such as
Lysophosphatidic Acid Enhances ASC Angiogenesis
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VEGF and FGF to promote vascularization. However, these
proteins are expensive and suffer from a characteristic, rapid
“burst” release profile when entrapped in hydrogels, making
sustained delivery challenging and potentially requiring the use
of high concentrations that can have undesirable side effects
[29,30]. For example, the localized or systemic administration
of high concentrations of recombinant VEGF has been
implicated in awakening dormant tumor cells or promoting the
growth of aberrant blood vessels that are quickly pruned
through vascular remodeling [31,32]. Although some groups
have pursued the covalent attachment of VEGF to a gel matrix
[33], the material-specific nature of the required chemistry limits
widespread applicability. As an alternative to protein release,
the delivery of self-assembling peptides with proangiogenic
molecules provides a method for more sustained presentation
[34,35], but such synthetic peptides must be carefully designed
for optimal non-immunogenicity and degradation properties for
each application.
Our findings describe a novel method for cell-based
angiogenesis that eliminates the need for costly recombinant
growth factors. Using LPA, an inexpensive glycerophospholipid
(~$10/mg versus ~$4,300/mg for VEGF and $12,000/mg for
angiopoietin [36]), we observed synergistically enhanced,
functional proangiogenic activity of ASC, a cell population that
has a well-described role in supporting endothelial cells and
neovascularization. Closely related lipid mediators such as
sphingosine-1-phosphate (S1P) [37] have been investigated for
their direct angiogenic effects on endothelial progenitor cells
[38,39], but less focus has been given to the mural cells that
are critical for stabilizing vessel formation and regulating
endothelial cell growth [40].
Although LPA stimulates VEGF production in rat stromal
cells [41] and human cancer cell lines [20] under ischemia,
such findings lack translational relevance because of
differences in chemokine receptor expression [42] and inter-
species inconsistencies in endogenous serum LPA levels. In
fact, LPA concentrations in plasma from Wistar rats are three
orders of magnitude higher than in FBS or human serum (data
not shown). Similarly, LPA from ovarian cancer cells increases
VEGF secretion in ASC [19], but the use of cell-conditioned
media containing a plethora of signaling molecules and
biologically variant concentrations of LPA is confounding and
thus not ideal for therapeutic angiogenesis.
Our in vitro results demonstrate that 25 μM LPA upregulates
ASC expression of VEGF and FGF2 under ischemic
conditions, and that these increases in transcriptional activity
are reflected by actual VEGF secretion. ASC also produced
more angiogenin, as well as TIMP-2, a matrix
metalloproteinase (MMP) inhibitor. RANTES (CCL5) and
MCP-1, both of which recruit monocytes and macrophages to
sites of inflammation [43], were secreted at higher levels as
well, suggesting that LPA may also have in vivo
immunomodulatory effects.
Furthermore, LPA-treated ASC are significantly more
effective at recruiting endothelial cells through paracrine
signaling. Although LPA alone promotes angiogenesis in a
chick chorioallantoic membrane (CAM) model [44], our results
specifically show that 25 μM LPA is not chemoattractive to
Figure 3.  ASC treated with LPA promote endothelial cell migration.  (a) Medium conditioned by ASC in the presence of LPA
under SD/H is significantly more chemoattractive to ECFC than medium from non-treated or inhibitor-treated ASC. The addition of
LPA or Ki16425 to unconditioned medium had no effect on ECFC migration (n = 5). (b) LPA promotes VEGF secretion from ASC
entrapped in 3D fibrin gels under SD/H compared to cells treated with no LPA or Ki16425. (n = 6). *p < 0.05 vs. control, **p < 0.01
vs. control, ***p < 0.001 vs. control (c) LPA also increases production of other angiogenic and inflammatory cytokines. Data are
presented as average subtracted background fluorescence intensity normalized to positive controls.
doi: 10.1371/journal.pone.0082134.g003
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human endothelial cells. Of particular relevance for clinical
applications, we successfully showed that ASC respond to LPA
in SD/H when incorporated in fibrin gels, without the need for
any preconditioning regimens. We also found that LPA1/3
inhibitor Ki16425 abolished all LPA-induced effects on ASC.
High levels of LPAR1 expression, coupled with the absence of
LPAR3, indicate that LPA1 mediates the angiogenic signaling of
LPA in human ASC. This is consistent with our findings that
LPA1 is responsible for anti-apoptotic and pro-angiogenic
effects of LPA in bone marrow-derived MSC [22].
Most importantly, we demonstrated that LPA maintains its
effects on ASC in vivo. We implanted fibrin-entrapped human
ASC in a severe model of critical limb ischemia that results in
rapid limb loss if untreated. The co-delivery of ASC and 25 μM
LPA improved functional outcome and significantly increased
blood vessel formation in the defect area within 2 weeks
compared to ASC alone, highlighting the exciting potential of
this treatment method. Although limbs treated with LPA alone
showed less overall limb loss, there was no corresponding
increase in blood vessel numbers at two weeks. Recent work
with S1P, a closely related bioactive lipid that also signals
through G-protein coupled receptors [45], demonstrated that
S1P recruits anti-inflammatory monocytes and M2
macrophages to blood vessels in inflamed and ischemic tissue
[46]. These findings, coupled with the LPA-mediated increase
in MCP-1 and RANTES, suggest that LPA alone may reduce
initial inflammation in situ, thus preserving more tissue at an
early stage. However, new blood vessel formation may be
limited without the additional proangiogenic factors secreted by
LPA-treated ASC.
Figure 4.  Co-delivery of LPA with ASC in fibrin gels significantly improves angiogenesis in a murine model of critical limb
ischemia.  Representative H&E stained sections from the quadriceps of (a) normal hindlimbs and (b) ischemic limbs treated with
fibrin gels containing 25 μM LPA, (c) ASC, or (d) LPA and ASC show the presence of more large vessels in limbs treated with cells
and LPA together. Similarly, CD31 staining reveals the formation of larger intramuscular blood vessels in limbs receiving (h) both
LPA and ASC, while (e) normal tissue and defects receiving (f) LPA and (g) ASC alone have fewer and smaller vessels. (i) Blood
vessel quantification from H&E stained sections confirms these results (n=8). Scale bars represent 100 μm; arrows indicative of
vessels with defined lumens and erythrocytes. *p < 0.05 vs. other groups. (j) Hindlimbs were visually assessed for severity of toe
and foot necrosis in each treatment group.
doi: 10.1371/journal.pone.0082134.g004
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Notably, the ability to synthesize fibrin gels containing cells
and LPA at the point of care lends itself readily to clinical
situations. Our treatment would be particularly effective if
combined with methods currently in development for rapidly
isolating and concentrating the stromal vascular fraction from
adipose tissue [47,48]. The ability to isolate and entrap
autologous ASC in LPA-containing fibrin gels and implant them
in a defect site during the course of a single surgery would
represent a significant advance over previous in vivo cardiac
studies that require rat MSCs to be preconditioned in vitro
before injection [41]. Overall, our results have broad
translational applications, including the possible treatment of
severe limb ischemia by co-delivery of LPA and autologous
ASC.
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